Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - rubella virus (ra 27/3 strain) - pdr+solv for soln for inj

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - measles virus; mumps virus; rubella virus; varicella virus - injection, powder, lyophilized, for solution - 3.00 log tcid 50/ dose - measles virus 3.00 log tcid 50/ dose; mumps virus 4.30 log tcid 50/ dose; rubella virus 3.00 log tcid 50/ dose; varicella virus 3.99 log pfu/ dose

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - measles virus strain enders' attenuated edmonston live antigen (unii: mfz8i7277d) (measles virus strain enders' attenuated edmonston live antigen - unii:mfz8i7277d), mumps virus strain b level jeryl lynn live antigen (unii: 47qb6mx9ku) (mumps virus strain b level jeryl lynn live antigen - unii:47qb6mx9ku), rubella virus strain wistar ra 27/3 live antigen (unii: 52202h034z) (rubella virus strain wistar ra 27/3 live antigen - unii:52202h034z), varicella-zoster virus strain oka/merck live antigen (unii: gpv - measles virus strain enders' attenuated edmonston live antigen 1000 [tcid_50] in 0.5 ml - proquad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age. do not administer proquad to individuals with a history of hypersensitivity to any component of the vaccine (including gelatin) {1} or to a previous dose of m-m-r ii (measles, mumps, rubella, live), proquad or varivax (varicella virus vaccine live) vaccine, or any other measles, mumps, and rubella or varicella-containing vaccine. do not administer proquad to individuals with a history of anaphylaxis to neomycin [see description (11)] . do not administer proquad vaccine to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. measles inclusion body encephalitis {2} (mibe), pneumonitis {3} and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. in this population, disseminated mump

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - rubella virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50; measles virus, quantity: 1000 ccid50; live varicella vaccine, quantity: 1995 pfu - injection, powder for - excipient ingredients: mannitol; sorbitol; lactose; threonine; serine; proline; glycine; alanine; valine; methionine; isoleucine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - live attenuated measles virus (schwarz strain) live attenuated mumps virus (rit 4385 strain) live attenuated rubella virus (wistar ra 27/3 strain) live attenuated varicella virus (oka strain) - pdr+solv for soln for inj

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - measles virus live attenuated derived from the edmonston b strain mumps virus - jerylynn strain rubella virus (wistar ra 27/3 strain) live attenuated - pdr+solv for soln for inj

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - live attenuated measles virus; live attenuated mumps virus; live attenuated rubella virus; live attenuated varicella virus - powder and solvent for solution for injection - live attenuated measles virus 10^ 3.0 ccid50; live attenuated mumps virus 10^ 4.4 ccid50; live attenuated rubella virus 10^ 3.0 ccid50; live attenuated varicella virus 10^ 3.3 pfu - measles, combinations with mumps, rubella and varicella, live attenuated - measles, combinations with mumps, rubella and varicella, live attenuated - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella in children from the age of 12 months up and including 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 1995 pfu; rubella virus, quantity: 1000 ccid50; measles virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50 - diluent, not applicable - excipient ingredients: water for injections - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - measles virus, quantity: 1000 ccid50; rubella virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50; live varicella vaccine, quantity: 1995 pfu - diluent, not applicable - excipient ingredients: water for injections - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - measles virus, quantity: 1000 ccid50; mumps virus, quantity: 5000 ccid50; rubella virus, quantity: 1000 ccid50 - diluent, not applicable - excipient ingredients: water for injections - priorix is indicated for active immunisation against measles, mumps and rubella from 12 months of age.